Bayer begins human testing of cancer vaccine derived from tobacco plants


It's possible the big breakthrough in cancer vaccines will come from one of the most ironic and unexpected of places—the good ol' tobacco plant.

Bayer Innovation has began a landmark clinical Phase I study of a patient-specific vaccine developed by obtaining proteins from tobacco plants using its proprietary "magnICON® technology". A small cohort of 20 patients previously treated with chemotherapy and in remission from B-cell non-Hodgkin's lymphomas will receive six vaccine injections over a six month period. Ideally, the vaccine should fire up the subject's immune system and direct it to attack malignant lymphoma cells.

By Ross Bonander


LymphomaInfo Social